See patient’s perspective of CAR T-cell therapy for Diffuse Large B-Cell Lymphoma. bit.ly/2KXmOkl. Glad to have been part of Zuma-1 trial that lead to FDA approval of Axi-Cel. Cleveland Clinic #CleClinicCancer, #lymphoma, #tcellrx

Join us 10/4 for the State of the Science Summit on Hematologic Malignancies with our chairs Brian Hill and Mikkael A. Sekeres MD, MS of Cleveland Clinic Cleveland Clinic MD Sign up now! consultqd.clevelandclinic.org/brian-hill-md-…

Re: Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival bit.ly/2Df2Ooq

Agree. High MRD undetectable rate, minimal toxicity with time-llimited therapy. No Btk inhibitor needed. #ASH2018

Venetoclax + RICE phase I trial results in diffuse large B-cell lymphoma presented by Dr. Paolo Caimi -- collaboration of Case Comp Cancer Ctr and Cleveland Clinic. High CR rate, tolerable SE profile, phase II trial upcoming. Brian Hill #CleClinicCancer #ASH18 #lymsm

Completely agree. Not sure why overall survival wasn’t in main text. Numerically, there are more deaths in ibrutinib arms, several due to, “unexpected causes.” I don’t think the message should be that every patient should ibrutinib indefinitely. #ASH18

Definitely. There is a lot of practice-impacting CLL data from ASH 2018 to discuss. @anthonymatomd #ASH18 MDedge Hematology & Oncology #MDedgeChats

Looking forward to lively Point/Counterpoint Discussion about maintenance therapy for follicular lymphoma with Mark Roschewski from @NCICCR_Lymphoma tomorrow at #ASCO19. #CleClinicCancer ascopubs.org/doi/full/10.12…

Our understanding of molecular features of Diffuse Large B-Cell Lymphoma has rapidly outpaced our treatment. Improving DLBCL outcomes will require cooperative effort to formally assess targeted therapies for this disease in the frontline setting. #CleClinicCancer

These data suggest that atrial fibrillation is a class effect of Btk inhibitors, rather than being unique to ibrutinib. #CleClinicMD #ASH19

Key takeaways from LOTIS-2 study leading to Loncastuximab approval in R/R DLBCL # Tweetorial #lymsm @ccarlostella Paolo F. Caimi Open-label; single arm; Single agent (important for efficacy data) No exclusion for pri refrac; double hit NOT excluded (1/10) thelancet.com/journals/lanon…

Many opinions about the POLARIX trial presented at #ASH21 late breaking session. See my take in < 2 minutes. #CleClinicCancer

Off-the-shelf CAR NK Cell therapy may be an option for #CLL & NHL patients unable to receive timely #CARTcell. Glad to have this trial with Nkarta, Inc. open at #ClevelendClinic in collaboration with Michael Dickinson and others Australian investigators. tinyurl.com/yr29en2w

Impressive long-term results of Phase III REMoDL-B trial highlight importance of testing targeted agents using molecular features (i.e GEP) for DLBCL. Addition of Bortezomib for ABC 5-year PFS 54% vs 69%, OS 67% vs 80% (p=0.032.) #ASH2022 tinyurl.com/suj6bvdb  #CleClinicCancer

Impressive long-term results of Phase III REMoDL-B trial highlight importance of testing targeted agents using molecular features (i.e GEP) for DLBCL. Addition of Bortezomib for ABC 5-year PFS 54% vs 69%, OS 67% vs 80% (p=0.032.) #ASH22 tinyurl.com/suj6bvdb  #CleClinicCancer

Congratulations to Deepa Jagadeesh, MD for representing #CleClinicCancer in the newly-published results of Pirtobrutinib in NEJM. Great to have more access to this important new treatment for our patients with #CLL, #CLLSociety nejm.org/doi/full/10.10…

Our real world data show modest single-agent activity of ibrutinib does not differ by DLBCL subtype. Need more widespread GEP in clinic. x.com/BloodJournal/s…

Impressive results with frontline venetoclax and obinutuzumab for CLL including high rates of MRD negativity. Do we even need Btk inhibitor? Hematology News. #ASH17. bit.ly/2BsyEOd

MURANO trial in R/R CLL(late breaking #ASH17): venetoclax-R vs BR associated with improved PFS (2-yr 85% vs 36%; HR 0.17, p<0.0001) and OS (92% vs 87%; HR 0.48) ash.confex.com/ash/2017/webpr… #cllsm

@CleveClinicCan Brian Hill on The ASCO Post; highly collaborative effort across 20+ US academic centers in #MantleCellLymphoma at #ASH17 #lymsm x.com/draevens/statu…